Cherradi, Sara
Garambois, Véronique
Marines, Johanna
Andrade, Augusto Faria
Fauvre, Alexandra
Morand, Olivia
Fargal, Manon
Mancouri, Ferial
Ayrolles-Torro, Adeline
Vezzo-Vié, Nadia
Jarlier, Marta
Loussaint, Gerald
Huvelle, Steve
Joubert, Nicolas
Mazard, Thibault
Gongora, Céline
Pourquier, Philippe
Boissière-Michot, Florence
Rio, Maguy Del
Funding for this research was provided by:
SIRIC Montpellier Cancer (INCa_Inserm_DGOS_12553)
Investissement D’avenir of the Labex MabImprove (ANR-10-LABX-53-01)
Ligue Contre le Cancer (Ligue Contre le Cancer)
Conseil Régional du Centre-Val de Loire (APR IR 2017)
Article History
Received: 8 November 2022
Accepted: 15 March 2023
First Online: 11 April 2023
Declarations
:
: BCB COLON (#NCT03976960) was approved by the French Ethics Committee CPP (Comité de Protection des Personnes) Sud Méditerranée III (Ref#2014.02.04). Tumor biobank (BB-0033-00059) samples were used after approval by the Montpellier Cancer Institute Institutional Review Board, following the national French ethical and legal guidelines for patient information and consent. All patients were informed before surgery that their anonymized surgical specimens might be used for research purposes. This study complies with all relevant ethical regulations for work with human participants, informed written consent was obtained for all patients, and our study was approved by the local translational research committee (ICM-CORT-2021-16). Animal studies were approved by the local ethics committee [Ethics Committee approved by the French Ministry, animal facility approval E34-172-27, and protocol approval CEEA-LR- 1381.
: Not applicable.
: The authors declare that they have no competing interests.